Review article: acute severe ulcerative colitis – evidence‐based consensus statements
Summary Background Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis. Aim To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome. Methods Following a literature revi...
Gespeichert in:
Veröffentlicht in: | Alimentary pharmacology & therapeutics 2016-07, Vol.44 (2), p.127-144 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 144 |
---|---|
container_issue | 2 |
container_start_page | 127 |
container_title | Alimentary pharmacology & therapeutics |
container_volume | 44 |
creator | Chen, J.‐H. Andrews, J. M. Kariyawasam, V. Moran, N. Gounder, P. Collins, G. Walsh, A. J. Connor, S. Lee, T. W. T. Koh, C. E. Chang, J. Paramsothy, S. Tattersall, S. Lemberg, D. A. Radford‐Smith, G. Lawrance, I. C. McLachlan, A. Moore, G. T. Corte, C. Katelaris, P. Leong, R. W. |
description | Summary
Background
Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis.
Aim
To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome.
Methods
Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre‐determined by ≥80% votes in ‘complete agreement’ or ‘agreement with minor reservation’.
Results
Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres.
Conclusion
These evidenced‐based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up‐to‐date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments. |
doi_str_mv | 10.1111/apt.13670 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1797231690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1797231690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4260-ff28e847f75393432766537b1c939eaf7e8ba3e8da4daf8ae7814e179be0f5413</originalsourceid><addsrcrecordid>eNp1kLtOwzAUQC0EoqUw8AMoIwxp_UjihK2qeEmVQKgMTJbjXEtBeRTbadWtn4DEH_ZLMKSwcZc73HPPcBA6J3hM_Ezk0o0JSzg-QEO_45BilhyiIaZJFtKUsAE6sfYNY-wZeowGlFOasCgaotdnWJWwDqRxpargOpCqcxBYWIGBoKsUGOnKFQSqrUpX2mC3_Qz8SwGNgt32I5cWCn9sLDS2s4F10kENjbOn6EjLysLZfo_Qy-3NYnYfzh_vHmbTeagimuBQa5pCGnHNY5axiFGeJDHjOVEZy0BqDmkuGaSFjAqpUwk8JREQnuWAdRwRNkKXvXdp2vcOrBN1aRVUlWyg7azwKKeMJBn26FWPKtNaa0CLpSlraTaCYPFdUviS4qekZy_22i6vofgjf9N5YNID67KCzf8mMX1a9MoveXp_2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797231690</pqid></control><display><type>article</type><title>Review article: acute severe ulcerative colitis – evidence‐based consensus statements</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Chen, J.‐H. ; Andrews, J. M. ; Kariyawasam, V. ; Moran, N. ; Gounder, P. ; Collins, G. ; Walsh, A. J. ; Connor, S. ; Lee, T. W. T. ; Koh, C. E. ; Chang, J. ; Paramsothy, S. ; Tattersall, S. ; Lemberg, D. A. ; Radford‐Smith, G. ; Lawrance, I. C. ; McLachlan, A. ; Moore, G. T. ; Corte, C. ; Katelaris, P. ; Leong, R. W.</creator><creatorcontrib>Chen, J.‐H. ; Andrews, J. M. ; Kariyawasam, V. ; Moran, N. ; Gounder, P. ; Collins, G. ; Walsh, A. J. ; Connor, S. ; Lee, T. W. T. ; Koh, C. E. ; Chang, J. ; Paramsothy, S. ; Tattersall, S. ; Lemberg, D. A. ; Radford‐Smith, G. ; Lawrance, I. C. ; McLachlan, A. ; Moore, G. T. ; Corte, C. ; Katelaris, P. ; Leong, R. W. ; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group</creatorcontrib><description>Summary
Background
Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis.
Aim
To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome.
Methods
Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre‐determined by ≥80% votes in ‘complete agreement’ or ‘agreement with minor reservation’.
Results
Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres.
Conclusion
These evidenced‐based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up‐to‐date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.13670</identifier><identifier>PMID: 27226344</identifier><language>eng</language><publisher>England</publisher><subject>Australia ; Colectomy - methods ; Colitis, Ulcerative - drug therapy ; Colitis, Ulcerative - therapy ; Consensus ; Cyclosporine - therapeutic use ; Hospitalization ; Humans ; Infliximab - therapeutic use ; Venous Thromboembolism - prevention & control</subject><ispartof>Alimentary pharmacology & therapeutics, 2016-07, Vol.44 (2), p.127-144</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4260-ff28e847f75393432766537b1c939eaf7e8ba3e8da4daf8ae7814e179be0f5413</citedby><cites>FETCH-LOGICAL-c4260-ff28e847f75393432766537b1c939eaf7e8ba3e8da4daf8ae7814e179be0f5413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.13670$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.13670$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27226344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, J.‐H.</creatorcontrib><creatorcontrib>Andrews, J. M.</creatorcontrib><creatorcontrib>Kariyawasam, V.</creatorcontrib><creatorcontrib>Moran, N.</creatorcontrib><creatorcontrib>Gounder, P.</creatorcontrib><creatorcontrib>Collins, G.</creatorcontrib><creatorcontrib>Walsh, A. J.</creatorcontrib><creatorcontrib>Connor, S.</creatorcontrib><creatorcontrib>Lee, T. W. T.</creatorcontrib><creatorcontrib>Koh, C. E.</creatorcontrib><creatorcontrib>Chang, J.</creatorcontrib><creatorcontrib>Paramsothy, S.</creatorcontrib><creatorcontrib>Tattersall, S.</creatorcontrib><creatorcontrib>Lemberg, D. A.</creatorcontrib><creatorcontrib>Radford‐Smith, G.</creatorcontrib><creatorcontrib>Lawrance, I. C.</creatorcontrib><creatorcontrib>McLachlan, A.</creatorcontrib><creatorcontrib>Moore, G. T.</creatorcontrib><creatorcontrib>Corte, C.</creatorcontrib><creatorcontrib>Katelaris, P.</creatorcontrib><creatorcontrib>Leong, R. W.</creatorcontrib><creatorcontrib>IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group</creatorcontrib><title>Review article: acute severe ulcerative colitis – evidence‐based consensus statements</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis.
Aim
To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome.
Methods
Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre‐determined by ≥80% votes in ‘complete agreement’ or ‘agreement with minor reservation’.
Results
Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres.
Conclusion
These evidenced‐based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up‐to‐date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments.</description><subject>Australia</subject><subject>Colectomy - methods</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Colitis, Ulcerative - therapy</subject><subject>Consensus</subject><subject>Cyclosporine - therapeutic use</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Infliximab - therapeutic use</subject><subject>Venous Thromboembolism - prevention & control</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLtOwzAUQC0EoqUw8AMoIwxp_UjihK2qeEmVQKgMTJbjXEtBeRTbadWtn4DEH_ZLMKSwcZc73HPPcBA6J3hM_Ezk0o0JSzg-QEO_45BilhyiIaZJFtKUsAE6sfYNY-wZeowGlFOasCgaotdnWJWwDqRxpargOpCqcxBYWIGBoKsUGOnKFQSqrUpX2mC3_Qz8SwGNgt32I5cWCn9sLDS2s4F10kENjbOn6EjLysLZfo_Qy-3NYnYfzh_vHmbTeagimuBQa5pCGnHNY5axiFGeJDHjOVEZy0BqDmkuGaSFjAqpUwk8JREQnuWAdRwRNkKXvXdp2vcOrBN1aRVUlWyg7azwKKeMJBn26FWPKtNaa0CLpSlraTaCYPFdUviS4qekZy_22i6vofgjf9N5YNID67KCzf8mMX1a9MoveXp_2Q</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Chen, J.‐H.</creator><creator>Andrews, J. M.</creator><creator>Kariyawasam, V.</creator><creator>Moran, N.</creator><creator>Gounder, P.</creator><creator>Collins, G.</creator><creator>Walsh, A. J.</creator><creator>Connor, S.</creator><creator>Lee, T. W. T.</creator><creator>Koh, C. E.</creator><creator>Chang, J.</creator><creator>Paramsothy, S.</creator><creator>Tattersall, S.</creator><creator>Lemberg, D. A.</creator><creator>Radford‐Smith, G.</creator><creator>Lawrance, I. C.</creator><creator>McLachlan, A.</creator><creator>Moore, G. T.</creator><creator>Corte, C.</creator><creator>Katelaris, P.</creator><creator>Leong, R. W.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201607</creationdate><title>Review article: acute severe ulcerative colitis – evidence‐based consensus statements</title><author>Chen, J.‐H. ; Andrews, J. M. ; Kariyawasam, V. ; Moran, N. ; Gounder, P. ; Collins, G. ; Walsh, A. J. ; Connor, S. ; Lee, T. W. T. ; Koh, C. E. ; Chang, J. ; Paramsothy, S. ; Tattersall, S. ; Lemberg, D. A. ; Radford‐Smith, G. ; Lawrance, I. C. ; McLachlan, A. ; Moore, G. T. ; Corte, C. ; Katelaris, P. ; Leong, R. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4260-ff28e847f75393432766537b1c939eaf7e8ba3e8da4daf8ae7814e179be0f5413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Australia</topic><topic>Colectomy - methods</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Colitis, Ulcerative - therapy</topic><topic>Consensus</topic><topic>Cyclosporine - therapeutic use</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Infliximab - therapeutic use</topic><topic>Venous Thromboembolism - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, J.‐H.</creatorcontrib><creatorcontrib>Andrews, J. M.</creatorcontrib><creatorcontrib>Kariyawasam, V.</creatorcontrib><creatorcontrib>Moran, N.</creatorcontrib><creatorcontrib>Gounder, P.</creatorcontrib><creatorcontrib>Collins, G.</creatorcontrib><creatorcontrib>Walsh, A. J.</creatorcontrib><creatorcontrib>Connor, S.</creatorcontrib><creatorcontrib>Lee, T. W. T.</creatorcontrib><creatorcontrib>Koh, C. E.</creatorcontrib><creatorcontrib>Chang, J.</creatorcontrib><creatorcontrib>Paramsothy, S.</creatorcontrib><creatorcontrib>Tattersall, S.</creatorcontrib><creatorcontrib>Lemberg, D. A.</creatorcontrib><creatorcontrib>Radford‐Smith, G.</creatorcontrib><creatorcontrib>Lawrance, I. C.</creatorcontrib><creatorcontrib>McLachlan, A.</creatorcontrib><creatorcontrib>Moore, G. T.</creatorcontrib><creatorcontrib>Corte, C.</creatorcontrib><creatorcontrib>Katelaris, P.</creatorcontrib><creatorcontrib>Leong, R. W.</creatorcontrib><creatorcontrib>IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, J.‐H.</au><au>Andrews, J. M.</au><au>Kariyawasam, V.</au><au>Moran, N.</au><au>Gounder, P.</au><au>Collins, G.</au><au>Walsh, A. J.</au><au>Connor, S.</au><au>Lee, T. W. T.</au><au>Koh, C. E.</au><au>Chang, J.</au><au>Paramsothy, S.</au><au>Tattersall, S.</au><au>Lemberg, D. A.</au><au>Radford‐Smith, G.</au><au>Lawrance, I. C.</au><au>McLachlan, A.</au><au>Moore, G. T.</au><au>Corte, C.</au><au>Katelaris, P.</au><au>Leong, R. W.</au><aucorp>IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review article: acute severe ulcerative colitis – evidence‐based consensus statements</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2016-07</date><risdate>2016</risdate><volume>44</volume><issue>2</issue><spage>127</spage><epage>144</epage><pages>127-144</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Acute severe ulcerative colitis (ASUC) is a potentially life‐threatening complication of ulcerative colitis.
Aim
To develop consensus statements based on a systematic review of the literature of the management of ASUC to improve patient outcome.
Methods
Following a literature review, the Delphi method was used to develop the consensus statements. A steering committee, based in Australia, generated the statements of interest. Three rounds of anonymous voting were carried out to achieve the final results. Acceptance of statements was pre‐determined by ≥80% votes in ‘complete agreement’ or ‘agreement with minor reservation’.
Results
Key recommendations include that patients with ASUC should be: hospitalised, undergo unprepared flexible sigmoidoscopy to assess severity and to exclude cytomegalovirus colitis, and be provided with venous thromboembolism prophylaxis and intravenous hydrocortisone 100 mg three or four times daily with close monitoring by a multidisciplinary team. Rescue therapy such as infliximab or ciclosporin should be started if insufficient response by day 3, and colectomy considered if no response to 7 days of rescue therapy or earlier if deterioration. With such an approach, it is expected that colectomy rate during admission will be below 30% and mortality less than 1% in specialist centres.
Conclusion
These evidenced‐based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up‐to‐date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments.</abstract><cop>England</cop><pmid>27226344</pmid><doi>10.1111/apt.13670</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-2813 |
ispartof | Alimentary pharmacology & therapeutics, 2016-07, Vol.44 (2), p.127-144 |
issn | 0269-2813 1365-2036 |
language | eng |
recordid | cdi_proquest_miscellaneous_1797231690 |
source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Australia Colectomy - methods Colitis, Ulcerative - drug therapy Colitis, Ulcerative - therapy Consensus Cyclosporine - therapeutic use Hospitalization Humans Infliximab - therapeutic use Venous Thromboembolism - prevention & control |
title | Review article: acute severe ulcerative colitis – evidence‐based consensus statements |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A40%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20article:%20acute%20severe%20ulcerative%20colitis%20%E2%80%93%20evidence%E2%80%90based%20consensus%20statements&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Chen,%20J.%E2%80%90H.&rft.aucorp=IBD%20Sydney%20Organisation%20and%20the%20Australian%20Inflammatory%20Bowel%20Diseases%20Consensus%20Working%20Group&rft.date=2016-07&rft.volume=44&rft.issue=2&rft.spage=127&rft.epage=144&rft.pages=127-144&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.13670&rft_dat=%3Cproquest_cross%3E1797231690%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797231690&rft_id=info:pmid/27226344&rfr_iscdi=true |